Publications and Research

Prognostic Significance of Biomarker Expression in Primary Ovarian Cancer

- I. Ibegbu MD, C. Wilste MD, Shala Masood MD, B. Ndubuisi MD
- 2) 'Guess who's coming to dinner' A case of vibrio vulnificus septicemia. Presented at the Florida Chapter of the ACP ASIM Annual Meeting, Gainsville, FL April 28-29,2001
- I. Ibegbu MD, L. Edwards MD
- 3) Dyslipdemia and cardiovascular morbidity

and mortality in hemodialysis patients; role of factors modulating cytosolic calcium.

Gadallah MF, El-shahaway M, Ibegbu E, Andrews G, Hanna D, Morkos A, Cooper M. Hemodialysis International February 2001

4) Association of colonic diverticula with adenomas and carcinomas, a colonoscopic experience in a University based hospital.

Sivert P, Ibegbu E, Lambiase L, Jijuan L.

Poster Presentation at the Digestive disease week May 19-24th 2001, Atlanta, GA

Association of colonic diverticula with adenomas and carcinomas, a colonoscopic experience in a University based hospital.

Sivert P, Ibegbu E, Lambiase L, Jijuan L.

Poster presentation at the Research day, University of Florida Health sciences center Jacksonville, FL May 23'd 2001

5) Cardiac Troponin T as a sensitive and specific predictor for acute myocardial infarction and its prognostic value for future cardiac events in a general hospital population.

A comparison of patients with and without acute coronary syndrome.

Ibegbu E, Conetta D.

6) Ativan vs Intravenous Alcohol.

A randomized trial for the treatment of alcohol

withdrawal

Koch K, Laos L, Ibegbu E, Gorospe W, House J, et al.

z) Association of Liver Steatosis & Chronic Hepatitis C. Eric Ibegbu, Jianjun Li, Ana Corregidor, et al.

Poster presentation at the Research day, University of Florida Health Sciences Center Jacksonville, FL

May 23'd 2001

Eric Ibegbu MD, Sunitha Pudotha MD, Carmela Monteiro MD. Ravi Kottol MD

9) Duodenal Somatostatinoma presenting as upper gastrointestinal bleeding and duodenal obstruction in a patient with neurofibromatosis.

A case report and review of the literature

10) Capsule Endoscopy in GI Practice

A Review of cases at a University Hospital. I. Ibegbu, L. Lambiase

11) Solid-pseudopapillary tumor of the pancreas (Frantz tumor) - a frequently misdiagnosed neoplasm of low malignant potential. A brief case report. Published: Practical gastroenterology Nov 2005 vol. XXIX No. 1J,E.Ibegbu MD, Y. Saloum MD, C. Fontanelli MD. Montedo MD

12) Short duration of time from a previous colonoscopy should not preclude a clinically indicated repeat colonoscopy. Presented at DDW as Poster May 2 1, 2005 and University of Florida Research day May I2'h 2005 Eric IbegbuMD, Anand Patel MD, David Ferris MD,

Galen Trussel RN, Louis Lambiase MD

13) Retrograde jejunogastric intussusception

A rare complication of gastrostomy tubes

A Case Report and Review of the Literature

Eric Ibegbu MD, Manish Relan MD, Kenneth J Vega MD World Journal of Gastroenterology 2007 October 2; 13(39): 5282-5284

I4) Incision vs. Non-incision technique of PEG Tube placement: Success rate and early complications.

Samvel A. Charukhchian, MD, Anand Patel, MD,

Eric Ibegbu, MD, Samir Habashi, MD, Louis Lambiase, MD, DI Division, University of Florida Health Sciences Center, Jacksonville, FL

Presented at the ACG Scientific meeting, Hawaii, 2005 American Journal of Gastroenterology Volume 100 Issue s9 page 5345 September 2005

- 15) Randomised clinical trials: "a novel rabeprazole extended-release 50mg formulation vsesomeprazole 40mg in healing of moderate to severe erosive oesophagitis the results of two double-blind studies" Presented at the Annual scientific meeting of the American College of Gastroenterology at San Antonio Texas in October 2010.
- 16) From Alimentary Pharmacology & Therapeutics Randomised Clinical Trial: A Novel Rabeprazole Extended Release 50 mg Formulation vs. Esomeprazole 40 mg in Healing of Moderate-to- severe Erosive Oesophagitis

L. Laine; P. O. Katz; D. A. Johnson; I. Ibegbu; M. J. Goldstein; C. Chou; G. Rossiter; Y. Lu Posted: 03/2 5/20 I I; Alimentary Pharmacology & herapeutics. 2011; 33(2):203-2I2. @ 20II Blackwell Publishing

Clinical Research Studies:

1) Pfizer

"Gastrointestinal randomized event and safety open label NSAID study (GI-REASONS): A randomized openJabel, blinded-endpoint, parallel- group trial of GI safety of Celecoxib compared with Non-selective nonsteroidal anti-inflammatory drugs (NSAIDS) in osteoarthritis patients.

PI: Ibegbu I.E

2) Procter & Gamble Pharmaceuticals/ QDIEM Study "Multi-center, investigator-blinded, randomized,

I2-month parallel-group, non-inferiority study to assess the efficacy and safety of QD dosing of Asacol compared to divided dosing in maintaining remission in patients with ulcerative colitis. PI: Ibegbu I.E

3) A Randomized Double-Blind Parallel Study of Rabeprazole Extended-Release 50mg versus Esomeperazole 40 mg for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)

P.I: Ibegbu LE

4) A Randomized Double-Blind Parallel Study of Rabeprazole Extended-release 50mg versus Esomperazole 40 mg for Healing and Symptomatic Relief of Mild to moderate Erosive Gasuoesophageal Reflux Disease (GERD)

P.I: Ibegbu I.E

- s) A Randomized Double-Blind Parallel Study of Rabeprazole Extended-release 50mg versus Ranitidine I50mg for maintenance of Healed Erosive Gastroesophageal Reflux Disease (GERD) P.I: Ibegbu I.E
- 6) A Multicenter Randomized Double-Blind Study to Compare the Efficacy, Safety and Tolerability of Rabeprazole ER 50 mg With Placebo in Subjects With Symptomatic Gastroesophageal Reflux Disease (SGERD)

P.I: Ibegbu LE

7) Centocor Research & Development

Phase 2,/3 Multicenter Randomized, Placebo- controlled, Double-Blinded study to Evaluate The Safety and Efficacy Of Golimumab Induction Therapy, Administered Intravenously, in subjects with Moderately to Severely Active Ulcerative Colitis.

8) Centocor Research & Development

Phase 3 Multicenter Randomized, Placebo- controlled, Double-Blinded study to Evaluate The Safety and Efficacy Of Golimumab Induction Therapy, Administered Intravenously, in subjects with Moderately to Severely Active Ulcerative colitis.

P.I: Ibegbu I.E

9) Centocor Research & Development

Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to evaluate the Efficacy and Safety of Ustekinumab Therapy in subjects with Moderately to Severely Active Crohn's Disease Previously Treated with TNF Antagonist Therapy.

P.I: Ibegbu I.E

10) Protocol C87075

A Non-Interventional Long-term Post-Marketing Registry of Patients Treated with Certolizumab Pegol (Cimzia@) for Crohn's Disease

P.I: Ibegbu I.E

11) sEcuRE

A Non-Interventional Long-Term Post-Marketing Registry of Patients Treated with Certolizumab Pegol (Cimzia) for Crohn's Disease

P.I: Ibegbu I.E 12) BUCF30ol

A Phase 3, Randomized, Double-Blind, Placebo Controlled, Multicenter Study to Assess the Efficacy and Safety of Budesonide Foam (2mg/25m1BID for 2 weeks, Followed By 2mg/25m1QD for 4 Weeks) Versus Placebo in Subjects with Active Mild to Moderate Ulcerative Proctitis or Proctosigmoiditis

P.I: Ibegbu I.E 13) ENABLE 2 Randomised, placebo-controlled, multi- center study to assess the efficacy and safety of eltrombopag in thrombocytopenic subjects With hepatitis C virus (HCV) infection who are otherwise eligible to initiate antiviral therapy (peginterferon alfa-2b plus ribavirin) 14) Furiex - Protocol 270189661853002

"A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-2 7018966 in the Treatment of Patients With Diarrhea-Predominant Irritable Bowel Syndrome".

P.L: Ibegbu LE.

- 1s) Salix Protocol RFIB3053/ Sub-Study RFIB3053LBT A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects with Irritable Bowel Syndrome with Diarrhea (IBS-D)
- I6) Epigenomics Protocol SPR002 2 Comparison of the performance of the Epi proColon and Fecal Immunochemical Test Post Colonoscopy in Subjects with Colorectal Cancer and Pre Colonoscopy in Subjects from a Guideline- Eligible Screening Population.

 17) Focus International Active Surveillance Study. Assess the risks of short and long term use of oral contraceptives. Analyze drug utilization pattern, representative of typical use of oral contraceptives. Characterize Folate intake with respect to diet, vitamin use, food fortification, etc I8)Single Fluid-Filled Intragastric Balloon for Weight Loss: US Post Regulatory Approval Multicenter Clinical

Experience in 316 Patients.

Vargas, Eric J.; Pesta, Carl M.; Bali, Ahmad; Ibegbu, Eric; Moore, Rachel L.; Kumbhari, Vivek; Sharaiha, Reem; Curry, Trace; Pitt, Tracy; Agnihotri, Abhishek; Dunlap, Margo K; Novikov, Aleksey A.; Ledonne, Erin;

Mundi, Manpreet; Acosta, Andres; Gostout, Christopher; Abu Dayyeh, Barham K.

19. EFFICACY OF ONLINE AFTERCARE PROGRAMS FOLLOWING INTRAGASTRIC BALLOON PLACEMENT FOR OBESITY IS SIMILAR TO TRADITIONAL FOLLOW UP: A LARGE PROSPECTIVE US MULTICENTER STUD Eric J. Vargas, Fateh Bazerbachi, Monika Rizk, Andrew C.Storm, Andres Acosta, Karen Grothe, Matt Clark, Manpreet Mundi, Carl M.Pesta, Ahmad Bali, Eric Ibegbu, Rachel L. Moore, Vivek Kumbhari, Trace Curry, Reem Z. Sharaiha, Christopher J. Gostout, K. Abu Dayyeh